WO2009059201A3 - Id2 as a target in colorectal carcinoma - Google Patents

Id2 as a target in colorectal carcinoma Download PDF

Info

Publication number
WO2009059201A3
WO2009059201A3 PCT/US2008/082079 US2008082079W WO2009059201A3 WO 2009059201 A3 WO2009059201 A3 WO 2009059201A3 US 2008082079 W US2008082079 W US 2008082079W WO 2009059201 A3 WO2009059201 A3 WO 2009059201A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
target
colorectal carcinoma
component
phospholipids
Prior art date
Application number
PCT/US2008/082079
Other languages
French (fr)
Other versions
WO2009059201A2 (en
Inventor
Lee M Ellis
Michael J Gray
Anil Sood
Gabriel Lopez-Berestein
Original Assignee
Univ Texas
Lee M Ellis
Michael J Gray
Anil Sood
Gabriel Lopez-Berestein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Lee M Ellis, Michael J Gray, Anil Sood, Gabriel Lopez-Berestein filed Critical Univ Texas
Publication of WO2009059201A2 publication Critical patent/WO2009059201A2/en
Publication of WO2009059201A3 publication Critical patent/WO2009059201A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are compositions that include a nucleic acid component that include a nucleic acid that inhibits the expression of a gene that encodes an inhibitor of DNA binding protein (Id), and a lipid component that includes one or more phospholipids. Also disclosed are methods of treating a subject with cancer that involve administering to the subject a pharmaceutically effective amount of a composition that includes a nucleic acid component that includes a nucleic acid that inhibits the expression of a gene that encodes Id2, and a lipid component comprising one or more phospholipids.
PCT/US2008/082079 2007-11-02 2008-10-31 Id2 as a target in colorectal carcinoma WO2009059201A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98507107P 2007-11-02 2007-11-02
US60/985,071 2007-11-02

Publications (2)

Publication Number Publication Date
WO2009059201A2 WO2009059201A2 (en) 2009-05-07
WO2009059201A3 true WO2009059201A3 (en) 2009-08-13

Family

ID=40591778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082079 WO2009059201A2 (en) 2007-11-02 2008-10-31 Id2 as a target in colorectal carcinoma

Country Status (1)

Country Link
WO (1) WO2009059201A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412939A (en) * 2014-08-12 2016-03-23 华中科技大学 Adriamycin co-drug-loading system and preparing method and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014005720A2 (en) 2011-09-15 2017-12-12 Genentech Inc method of selecting and / or identifying a usp1 antagonist, uaf1 antagonist and / or an id antagonist that promotes a change in the cellular fate of said method
KR20200002866A (en) * 2017-03-29 2020-01-08 인스티튜트 오브 베이직 메디컬 사이언시즈, 차이니즈 아카데미 오브 메디컬 사이언시즈 Application of Compounds or Traditional Chinese Pharmaceutical Extracts in the Preparation of Nucleic Acid Delivery Agents and Related Products thereof
US20210100905A1 (en) * 2018-03-29 2021-04-08 Institute Of Basic Medical Sciences Chinese Academy Of Medicalsciences Application of compound or traditional chinese medicine extract in preparation of nucleic acid delivery agent, and related products
EP4056552A4 (en) * 2019-11-08 2023-11-29 Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Use of lipid in preparation of nucleic acid delivery reagent and related product thereof
WO2022241077A1 (en) * 2021-05-14 2022-11-17 The Trustees Of Columbia University In The City Of New York Tumor immunotherapy
CN115364111B (en) * 2021-05-17 2024-04-02 中国医学科学院基础医学研究所 Application of glycerophospholipids compound in treatment of tumor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FONG, S. ET AL.: "Id Genes and Proteins as Promising Targets in Cancer Therapy.", TREND. MOL. MED., vol. 10, no. 8, August 2004 (2004-08-01), pages 387 - 392 *
HALDER, J. ET AL.: "Focal Adhesion Kinase Targeting Using in vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.", CLIN. CANCER RES., vol. 12, no. 16, August 2006 (2006-08-01), pages 4916 - 4924 *
KLEEFF, J. ET AL.: "The Helix-Loop-Helix Protein Id2 Is Overexpressed in Human Pancreatic Cancer.", CANCER RES., vol. 58, September 1998 (1998-09-01), pages 3769 - 3772 *
LANDEN, C. N. ET AL.: "Intraperitoneal Delivery of Liposomal siRNA for Therapy of Advanced Ovarian Cancer.", CANCER BIOL. THER. DEV., vol. 5, no. 12, 2006, pages 1708 - 1713 *
LANDEN, C. N. ET AL.: "Therapeutic EphA2 Gene Targeting in vivo Using Neutral Liposomal Small Interfering RNA Delivery", CANCER RES., vol. 65, no. 15, August 2005 (2005-08-01), pages 6910 - 6918 *
LASORELLA, A. ET AL.: "Id2 Mediates Tumor Initiation, Proliferation, and Angiogenesis in Rb Mutant Mice.", MOL. CELL. BIOL., vol. 25, no. 9, May 2005 (2005-05-01), pages 3563 - 3574 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412939A (en) * 2014-08-12 2016-03-23 华中科技大学 Adriamycin co-drug-loading system and preparing method and application thereof
CN105412939B (en) * 2014-08-12 2018-08-03 华中科技大学 A kind of adriamycin co-supported medicine system, preparation method and application

Also Published As

Publication number Publication date
WO2009059201A2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2009059201A3 (en) Id2 as a target in colorectal carcinoma
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2008043753A8 (en) Rna antagonist compounds for the modulation of pcsk9
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
WO2008074328A3 (en) Microrna target site blocking oligos and uses thereof
WO2007064857A8 (en) Amphoteric liposome formulation
WO2007118245A3 (en) Methods and compositions related to adenoassociated virus-phage particles
WO2008042973A3 (en) Lipid containing formulations
WO2008114262A3 (en) Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer
WO2007098611A8 (en) Compositions for treatment of cancer
WO2008030883A3 (en) Treatment of cancer
WO2009070244A3 (en) Methods for inhibiting fascin
WO2007084986A3 (en) Compositions and methods for preventing or treating feline chronic kidney disease
WO2010065961A3 (en) Compositions and methods relating to mir-31
WO2008061108A3 (en) Phthalazine derivatives
WO2009070609A3 (en) Therapeutic targeting of il-6 using sirna in neutral liposomes
WO2008092099A3 (en) Compositions and methods for treating hematopoietic malignancies
WO2007103876A3 (en) Cancer therapeutic
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2009099959A3 (en) Tumor cell expression of neuropilin as a target for cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08845567

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08845567

Country of ref document: EP

Kind code of ref document: A2